Is NOVT a Buy or a Sell? The Bull and Bear Case (2026)
Last updated October 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Novanta (NOVT) rests on Medical Solutions demand: The Medical Solutions segment, which serves minimally invasive surgery, life sciences instrumentation, and patient monitoring, is roughly half of revenue and a key growth engine. The bear case rests on novanta trades at a high price-to-earnings multiple (about 83x trailing and 30x forward as of October 2026), so any shortfall in growth or margins can drive sharp share-price moves, as the roughly 10% decline over the past three months shows. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Novanta Inc. is a specialized technology company that designs and manufactures photonics, precision motion, and vision components and sub-systems, which it sells to original equipment manufacturers (OEMs) in medical and advanced industrial markets worldwide. Its products include laser scanning and beam-steering systems, precision motors and encoders, machine-vision components, radio-frequency and surgical technologies, and other embedded devices that go inside customers' larger machines. The company organizes itself into two reporting segments: Medical Solutions, which serves minimally invasive surgery, life sciences, and patient monitoring, and Automation Enabling Technologies, which serves robotics, industrial automation, laser materials processing, and semiconductor and electronics manufacturing. Medical end markets represent a bit over half of revenue and advanced industrial the rest. Novanta grows through a mix of organic gains in its OEM franchises and a steady cadence of bolt-on acquisitions that add technology and expand its addressable market. The investment picture is that of a diversified precision-components compounder: modest single-digit organic growth in a typical year, higher reported growth when acquisitions are added, and expanding adjusted margins, all of which the market has historically rewarded with a premium valuation. The trade-off is that the stock's high price-to-earnings multiple makes it sensitive to any slowdown in medical or industrial capital spending, integration missteps, or margin pressure, so the shares can be volatile around earnings and macro shifts. The 2026 numbers so far have supported the growth case. Second-quarter revenue (quarter ended July 3, 2026) was about $266 million, up roughly 10% from a year earlier, and adjusted EPS of $0.89 beat the ~$0.83 consensus, the fourth straight quarterly beat. Trailing revenue has reached about $1.03 billion. The stock has been choppy, though: it sits about 10% below where it was three months ago and well under its 52-week high near $176, even while it remains up for the year.
The bull case for NOVT
1. Medical Solutions demand.
The Medical Solutions segment, which serves minimally invasive surgery, life sciences instrumentation, and patient monitoring, is roughly half of revenue and a key growth engine. Novanta supplies embedded photonics, motion, and radio-frequency technologies to medical-device OEMs, giving it exposure to durable healthcare spending trends. Demand here tends to be less cyclical than industrial markets, which supports steadier revenue.
2. Automation and robotics.
The Automation Enabling Technologies segment sells precision motion, machine vision, and laser components into robotics, industrial automation, and laser materials processing. Novanta reported strong bookings growth with a book-to-bill ratio above 1.0 in early fiscal 2026, pointing to recovering order momentum, and it increasingly shows up in market commentary as a robotics and AI-automation supplier. This unit ties Novanta to long-run automation and reshoring themes, though it is more sensitive to the industrial capital-spending cycle.
3. Acquisitions and margin expansion.
Novanta has a long track record of bolt-on acquisitions that add proprietary technology, broaden its OEM relationships, and expand its addressable market. Management pairs this with a focus on adjusted EBITDA margin expansion and pricing discipline. The balance sheet gives it room: about $719 million of cash against roughly $286 million of debt at the latest quarter. Successful integration is central to the growth story, since much of the company's reported revenue growth in a given year can come from deals rather than pure organic gains.
4. Order momentum turning into revenue.
In its Q1 fiscal 2026 report, Novanta cited bookings up about 37% year over year and raised its full-year outlook. Revenue then grew about 10% in the second quarter, and analysts now expect roughly $301 million of revenue and $0.97 of EPS for the third quarter, with full-year 2026 revenue estimates near $1.13 billion and 2027 EPS estimates around $4.37. Whether that building backlog converts into sustained organic growth will be tested again when the company reports on November 9, 2026.
The bear case for NOVT
Novanta trades at a high price-to-earnings multiple (about 83x trailing and 30x forward as of October 2026), so any shortfall in growth or margins can drive sharp share-price moves, as the roughly 10% decline over the past three months shows. A large share of revenue comes from advanced industrial and semiconductor-adjacent markets that are cyclical and can slow quickly when customers cut capital spending. The company depends heavily on acquisitions for growth, which brings integration, goodwill, and balance-sheet risk if deals underperform, and GAAP profit margins remain thin at about 6%. Because Novanta sells components embedded inside OEM products, it has customer-concentration and design-win risk, and results can be pressured by tariffs, supply-chain costs, and foreign-exchange swings given its global manufacturing and sales footprint.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding NOVT already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on NOVT
Too few analysts publish on NOVT for a consensus target to mean anything, so there is no professional average to weigh against your own view. That cuts both ways: less informed opinion to lean on, and less of it already priced in. The NOVT forecast page covers what coverage does exist.
How is NOVT valued? (as of October 2026)
Snapshot for NOVT as of October 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$1.03 billion
- Q2 FY2026 revenue: ~$266 million (up ~10% YoY)
- Margins (gross / operating / net): ~45% / ~12% / ~6%
- Net income (TTM): ~$62 million
- Market cap: ~$5.0 billion
- P/E (trailing): ~83x
- P/E (forward): ~30x
- Dividend yield: None
Novanta still trades at a rich valuation, with a trailing price-to-earnings ratio near 83x and a forward multiple around 30x, down from roughly 100x and 41x in mid-2026 as the share price eased and earnings estimates rose. GAAP earnings are held down by acquisition-related amortization and stock compensation, so the company and analysts emphasize adjusted EPS, which has beaten consensus in each of the last four quarters. The next test is third-quarter results on November 9, 2026, where consensus sits near $0.97 of EPS on about $301 million of revenue.
How do you decide if NOVT is a buy?
Rather than asking whether NOVT is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold NOVT indirectly through an index or sector ETF before adding more.
What would change your mind on NOVT
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Medical Solutions demand stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: novanta trades at a high price-to-earnings multiple (about 83x trailing and 30x forward as of October 2026), so any shortfall in growth or margins can drive sharp share-price moves, as the roughly 10% decline over the past three months shows fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the NOVT stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about NOVT against your real portfolio and see your actual exposure before deciding.
Investing in Novanta with AI
Connect the broker you already use and ask Walnut's AI how NOVT fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is NOVT a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Medical Solutions demand, with revenue (ttm) at ~$1.03 billion. The bear case rests on novanta trades at a high price-to-earnings multiple (about 83x trailing and 30x forward as of October 2026), so any shortfall in growth or margins can drive sharp share-price moves, as the roughly 10% decline over the past three months shows. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell NOVT?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Novanta trades at a high price-to-earnings multiple (about 83x trailing and 30x forward as of October 2026), so any shortfall in growth or margins can drive sharp share-price moves, as the roughly 10% decline over the past three months shows. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. Walnut is not an investment adviser.
What is the bull case for NOVT?
+
Medical Solutions demand. The Medical Solutions segment, which serves minimally invasive surgery, life sciences instrumentation, and patient monitoring, is roughly half of revenue and a key growth engine.
What is the bear case for NOVT?
+
Novanta trades at a high price-to-earnings multiple (about 83x trailing and 30x forward as of October 2026), so any shortfall in growth or margins can drive sharp share-price moves, as the roughly 10% decline over the past three months shows. A large share of revenue comes from advanced industrial and semiconductor-adjacent markets that are cyclical and can slow quickly when customers cut capital spending. The company depends heavily on acquisitions for growth, which brings integration, goodwill, and balance-sheet risk if deals underperform, and GAAP profit margins remain thin at about 6%. Because Novanta sells components embedded inside OEM products, it has customer-concentration and design-win risk, and results can be pressured by tariffs, supply-chain costs, and foreign-exchange swings given its global manufacturing and sales footprint.
What does Novanta do?
+
Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally.
What would have to change for NOVT to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Medical Solutions demand) stalling in the reported numbers rather than in the narrative, the risk above (novanta trades at a high price-to-earnings multiple (about 83x trailing and 30x forward as of October 2026), so any shortfall in growth or margins can drive sharp share-price moves, as the roughly 10% decline over the past three months shows) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Novanta do?
+
Novanta is a precision technology company that designs and manufactures photonics, precision motion, and vision components and sub-systems. It sells these to original equipment manufacturers in medical and advanced industrial markets, where its parts are embedded inside customers' larger machines and instruments.
What are Novanta's business segments?
+
Novanta reports two segments: Medical Solutions, which serves minimally invasive surgery, life sciences, and patient monitoring, and Automation Enabling Technologies, which serves robotics, industrial automation, laser materials processing, and electronics manufacturing. Medical end markets are a bit over half of revenue and advanced industrial the rest.
How much revenue does Novanta generate?
+
Novanta generates roughly $1.03 billion in trailing-twelve-month revenue as of October 2026. Its second-quarter fiscal 2026 revenue was about $266 million, up around 10% year over year, after about $258 million in the first quarter. Analysts expect full-year 2026 revenue of roughly $1.13 billion.
Walnut is informational, not investment advice, and gives no verdict on NOVT. Analyst targets referenced here come from a October 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.